Hematological findings and complications of COVID-19. This multicenter, retrospective, observational study collected data from 47 nephrology clinics in Turkey. We conducted a matched cohort study. A total of 167 patients with severe COVID-19, including 55 diabetic patients and 112 nondiabetic patients at Tongji Hospital, Wuhan, China from January 28, 2020, to March 10, 2020, …  JAMA . We studied patients with proven COVID-19 disease in the intensive care unit of Jinyintan Hospital, Wuhan, China from 30 to 2019 to 31 March 2020. Circ Res. Documented CNS manifestations such as encephalopathy, stroke, seizure, and syncope are relatively common, being present in at least 13% of hospitalized patients with COVID-19, although the incidence is likely much higher. PURPOSE SARS-CoV-2 (COVID-19) is a systemic infection. Circulating platelets as mediators of immunity, inflammation, and thrombosis. Introduction : SARS-COV-2 disease 2019 has emerged as a major global health threat with a great number of deaths in the world amounting to nearly 8 lakhs. To our knowledge, this is the largest study analyzing the neurologic manifestations of COVID-19 and their effect on mortality. Published online September 2, 2020. doi: 10.1001/jama.2020.17023 Google Scholar The objective of current study is to analyze the vitamin D level in COVID-19 patients and its impact on the disease severity. We also confirmed that previously known prognostic laboratory markers associated with higher mortality, including lymphopenia, thrombocytopenia, elevated serum creatinine, lactic acidosis, and elevated procalcitonin, all seemed to be significant risk factors for hospitalized patients with cancer and COVID‐19 in the multivariate analysis. Previous published prognostic models for COVID-19 patients have been suggested to be prone to bias due to unrepresentativeness of patient population, lack of external validation, inappropriate statistical analyses, or poor reporting. doi: 10.1111/jth.14848 Crossref Medline Google Scholar; 75. EMA’s safety committee has concluded today that unusual blood clots with low blood platelets should be listed as very rare side effects of Vaxzevria (formerly COVID-19 Vaccine AstraZeneca).In reaching its conclusion, the committee took into consideration all currently available evidence, including the advice from an ad hoc expert group. Coronavirus disease– 2019 (COVID-19) is a disease that was detected in December 2019 in Wuhan, China, and led to the risk of mortality of about 2% [].This disease is caused due to infection with a recently arising zoonotic virus known as the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [].Previously, infection with coronaviruses appeared in 2002 within … Patients with cancer are immunocompromised and may be vulnerable to COVID-related morbidity and mortality. About 20%–55% of patients admitted to hospital for coronavirus disease 2019 (COVID-19) have laboratory evidence of coagulopathy. 2020;18(6):1469–72. 7 Yang X, Yang Q, Wang Y, et al. According to our results, every 1 unit increase in MPV increased mortality by 1.76 times. Chi-square, Fisher's exact, and the Mann-Whitney U-tests were used to … Thrombocytopenia and its association with mortality in patients with COVID-19. J Thromb Haemost. under study rates of covid-19 cases in the UK increased steeply, putting hospital services under strain, which in turn affected mortality14 and potentially biased observations of mortality. Maintenance hemodialysis (MHD) patients are at increased risk for coronavirus disease 2019 (COVID-19). In a large population of patients admitted to hospital with COVID-19, disease outcomes were better predicted by frailty than either age or comorbidity. Pooled analyses of prospective cohort studies with historical controls have shown that untreated HIT can be complicated by further thrombotic events in 30-75% of cases with 5-10% mortality. In contrast, a study of 24 critically ill COVID-19 patients in Seattle with a 50 percent mortality rate found elevated troponin levels early after intensive care unit admission in only 2 of 13 (15 percent) tested patients, but troponin assays may have differed . The coronavirus disease 2019 (COVID-19) global pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused considerable morbidity and mortality in over 170 countries. A high-quality and easy-to-use prognostic model to predict in-hospital mortality for COVID-19 patients could support physicians to make better clinical decisions. Since the first diagnosis on February 3rd, the epidemic has quickly evolved, with Belgium at the crossroads of Europe, being one of the hardest hit countries. J Thromb Haemost. Yang X, Yang Q, Wang Y, Wu Y, Xu J, Yu Y, Shang Y. Thrombocytopenia and its association with mortality in patients with COVID-19. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Koupenova M, Clancy L, Corkrey HA, Freedman JE. The objectives of this study were to determine if patients with cancer have worse outcomes compared with patients without cancer and to identify demographic and clinical predictors of morbidity and mortality among patients … 86.6% of death events occurred within 90 days, and 66.67% of them occurred within 28 days, which means this disease developed rapidly and led to death in a short time in high-risk patients. Thrombocytopenia and its association with mortality in patients with COVID-19. Thrombocytopenia occurs in one-third of patients with coronavirus disease 2019 (COVID-19) infection and can indicate the severity of disease and may also increase the bleeding risk of performing invasive procedures. The mechanism of change in platelet indices in COVID-19 patients is probably multifactorial. Objectives: An outbreak of coronavirus disease (COVID-19) in 2019 in Wuhan, China, has spread quickly worldwide. Although risk factors for severe disease in COVID-19 patients have been described in Chinese and United States (US) … EU regulators have started a review to assess reports of low blood platelets in patients who received any of the three approved COVID-19 vaccines from … Nand S, Wong W, Yuen B, et al. Introduction. Obesity is one of the strongest predictors of severe disease and mortality in COVID-19 12 and is a well-known risk factor for thromboembolic complications generally. Thrombocytopenia (platelet count < 150,000/μl) is common in critically ill patients, with an estimated incidence of 20%–40% at some point during the intensive care unit (ICU) stay [].Thrombocytopenia is recognized as an independent risk factor for mortality in ICU patients [2, 3].Both the nadir platelet count and a large drop in platelet count predict a poor outcome in adult ICU patients []. J Thromb Haemost 2020;18:1469–72. To our knowledge, this study is the first one specialized in the association between platelet indices and in-hospital mortality in patients with COVID-19. However, the risk factors associated with COVID-19-related mortality remain controversial.Methods: A total of 245 adult patients with laboratory-confirmed COVID-19 from two centers were analyzed. Coronavirus disease 2019 (COVID-19) is associated with coagulation abnormalities which are indicators of higher mortality especially in severe cases. To deal with bias from the varied geographical and temporal incidence of covid-19 and its burden on hospitals we EMA confirms overall benefit-risk remains positive. The coronavirus disease 2019 (COVID-19) pandemic has affected more than 12 million people and caused more than 500,000 deaths worldwide. COVID-19 is caused by Severe Acute Respiratory Syndrome Coronavirus-2, which has infected over thirty eight million individuals worldwide. The mortality rate of patients with COVID‐19 who did not have hematologic disorders was 23.5%, which was significantly lower than the mortality rate of hematologic patients with COVID‐19 when they were matched for sex, age, comorbidities, and respiratory failure at presentation (P = .023 [Fisher exact test]). Coagulopathy correlates with severity of COVID-19 and may include increased d-dimer concentrations (≥ 2 times above normal range), mildly prolonged prothrombin time (~ 1–3 s prolongation above normal range), mild thrombocytopenia (platelet count > 100 ×10 9 … Thrombocytopenia and its association with mortality in patients with COVID-19. Increasing age and burden of cardiovascular comorbidities are associated with a worse prognosis among patients with COVID-19. Emerging evidence indicates that COVID-19 patients are at a high risk of developing coagulopathy and thrombosis, conditions that elevate levels of D-dimer. Our study also confirmed that thrombocytopenia was associated with mortality in critically ill COVID-19 patients. The aim of this study was to describe clinical, laboratory, and radiologic characteristics and determinants of mortality in a large group of MHD patients hospitalized for COVID-19. 2020; 18 : 1469-1472 View in Article J Thromb Haemost. 8 Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Methods: We performed a retrospective chart review of 4131 COVID-19 positive adult patients who were admitted to 3 tertiary care hospitals of an academic medical center at the epicenter of the COVID-19 pandemic in New York City from March 1, 2020, to May 10, 2020, to identify patients who had magnetic resonance imaging (MRI) of the brain. Patients with heparin-induced thrombocytopenia present with mild thrombocytopenia or a 50 percent decrease in platelet count from baseline.22 The incidence is higher among surgical patients … Am J Hematol 2020;95:834–47. We present a pregnant patient with COVID-19 infection with the lowest platelet count described in the literature to date. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. CAS Article Google Scholar 16. Diabetes is one of the most common comorbidities in adult patients with coronavirus disease 2019 (COVID-19). 2020; 18:1469–1472. This study aimed to analyze the mortality risk factors of diabetic patients with COVID-19. Our results support the use of CFS to inform decision making about medical care in adult patients admitted to hospital with COVID-19. Belgium was among the first countries in Europe with confirmed coronavirus disease 2019 (COVID-19) cases.